Moderna narrows operating loss 10% as EU approves flu-COVID combo; $950M settlement paid in July

Filed July 31, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 1, 2025 · ~2 min read

Key Changes

• high

  Operating loss narrowed 10% YoY to $815M despite $884M litigation settlement charge in cost of sales; settlement with Arbutus/Genevant paid in July 2026, removing overhang.

  MD&A: Cost of Sales & Operating Results verify on EDGAR →
• high

  European Commission approved mCOMBRIAX (flu plus COVID combo vaccine) in April 2026 for adults 50+, expanding respiratory portfolio to four authorized products across EU member states.

  MD&A: Product Approvals verify on EDGAR →
• high

  FDA advisory committee voted unanimously in June 2026 that benefits of mRNA-1010 seasonal flu vaccine outweigh risks for adults 50+; PDUFA goal date August 5, 2026.

  MD&A: Regulatory Milestones verify on EDGAR →